Irenic Capital Management LP Makes New Investment in Vor Biopharma Inc. $VOR

Irenic Capital Management LP purchased a new position in Vor Biopharma Inc. (NASDAQ:VOR) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 32,663 shares of the company’s stock, valued at approximately $583,000. Irenic Capital Management LP owned 0.06% of Vor Biopharma at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. UBS Group AG grew its holdings in Vor Biopharma by 284.8% in the fourth quarter. UBS Group AG now owns 292,118 shares of the company’s stock valued at $3,821,000 after purchasing an additional 216,209 shares during the last quarter. Frazier Life Sciences Management L.P. purchased a new stake in shares of Vor Biopharma in the fourth quarter valued at $33,275,000. NEXTBio Capital Management LP purchased a new stake in shares of Vor Biopharma in the fourth quarter valued at $13,080,000. Simplify Asset Management Inc. purchased a new stake in Vor Biopharma during the 1st quarter worth about $955,000. Finally, Findell Capital Management LLC acquired a new position in Vor Biopharma in the 4th quarter valued at about $3,021,000. 97.29% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have commented on VOR. Weiss Ratings raised shares of Vor Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 30th. Wall Street Zen cut shares of Vor Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Wedbush increased their target price on Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. Jefferies Financial Group upgraded Vor Biopharma to a “strong-buy” rating in a report on Thursday, April 30th. Finally, HC Wainwright restated a “buy” rating and set a $31.00 price target on shares of Vor Biopharma in a research note on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.25.

Vor Biopharma Price Performance

Vor Biopharma stock opened at $20.00 on Wednesday. Vor Biopharma Inc. has a 52-week low of $6.50 and a 52-week high of $53.00. The firm has a fifty day moving average of $16.48 and a 200-day moving average of $15.36.

Vor Biopharma (NASDAQ:VOR) last issued its earnings results on Monday, March 30th. The company reported $307.61 EPS for the quarter. On average, sell-side analysts predict that Vor Biopharma Inc. will post -2.51 EPS for the current fiscal year.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).